Life science is complicated, but its mission is simple – to create a safer, healthier future. This podcast tells the stories behind the science from the perspective of patients, scientists, employees, and advocates that have felt its impact.
Being the parent of a child with an ultra-rare disease can be a daunting challenge.
Nasha Fitter is no different. Her daughter Amara is nonverbal and suffers from epileptic seizures, two of the common symptoms associated with her eventual diagnosis of an ultra-rare neurodevelopmental disorder known as FOXG1 Syndrome. Motivated by her desire to learn more about this condition, she co-founded the FOXG1 Research Foundation (FRF) with her fellow peers.
Through all the challenges they’ve faced, Nasha and FRF are set to conduct critical research in the hopes of developing a treatment for not just this condition, but other ultra-rare diseases primarily affecting children to eventually give them “the life they deserve.”
Join us as we conclude season five where Nasha discusses the origins of FRF, how Amara’s life has been shaped by her diagnosis, how collaboration has helped advance the Foundation’s mission, and what you can do to support their ultimate goals.
Show Notes
FOXG1 Research Foundation (https://foxg1research.org/)
FOXG1 Research Foundation's Nasha Fitter Speaks at the White House Rare Disease Forum (https://www.youtube.com/watch?v=oKzedIgO_EY&feature=youtu.be)
Rare Disease | Charles River (https://www.criver.com/therapeutic-area/rare-disease)
CRISPR/Cas9 Gene Editing | Charles River (https://www.criver.com/products-services/discovery-services/screening-and-profiling-assays/assay-development/crispr-gene-editing?region=3601)
ASO Screening and Profiling (https://www.criver.com/products-services/discovery-services/screening-and-profiling-assays/high-throughput-screening/antisense-olignonucleotide-screening?region=3601)
18 Jun 2024
Cure EB: Healing the Wounds
Imagine giving birth to a baby girl and noticing pieces of skin missing from her body almost immediately.
For Sharmila Nikapota, this was the case with her firstborn, Sohana. Genetic testing revealed that she was one of the over 500,000 people globally suffering from Epidermolysis Bullosa (EB), a “constantly painful and debilitating” skin condition where minimal contact can lead to blisters, wounds, tissue damage, eating difficulties, and eye injuries, among other symptoms. After seeking answers for her daughter’s prognosis and not getting any, Sharmila started Cure EB to educate people and eventually discover ways to manage this painful condition. With the UK approving a first-of-its-kind topical treatment for EB, she hopes it’s the first of many that can give patients like her daughter a better quality of life.
Join Sharmila as she discusses how Sohana’s experience with EB has shaped her personality, the origin and mission of Cure EB, the challenges of managing Sohana’s condition, and what you can do to further Cure EB’s ultimate goals.
Show Notes
Cure EB - Accelerating Research to End Painful Skin (https://cure-eb.org/what-is-eb/)
Birch Bark Extract: A Review in Epidermis Bullosa (https://pubmed.ncbi.nlm.nih.gov/37658982/#:~:text=Birch%20bark%20extract%20(Filsuvez%C2%AE,and%20junctional%20epidermolysis%20bullosa%20(EB)
Charles River | Cell and Gene Therapy (https://www.criver.com/molecule-type/cell-and-gene-therapy-services)
Charles River | Rare Disease (https://www.criver.com/therapeutic-area/rare-disease)
Eureka Blog | Living Rare (https://www.criver.com/eureka/living-rare)
Krystal Biotech Touts Topical Gene Therapy Uptake (https://www.fiercepharma.com/pharma/krystal-biotechs-topical-gene-therapy-launch-barrels-ahead-overseas-launched-slated-2025?utm_medium=email&utm_source=nl&utm_campaign=LS-NL-FiercePharma&oly_enc_id=6677D9171445A5K)
21 May 2024
Clear Scientific: Combatting Drug Overdose from Methamphetamine, Fentanyl, and Polydrug
Stimulant use in the United States has exploded into a nationwide crisis, as deaths and emergency room visits resulting from methamphetamine and cocaine use are rising at an alarming rate.
The overall substance abuse disorder crisis is further exacerbated by the high level of fentanyl use, which has long been referred to as an opioid epidemic, and the increasing use of more than substance at once. One fundamental limitation on the ability to respond to the crisis is that, to date, there is no FDA-approved therapeutic to treat overdose from stimulants like methamphetamine and cocaine, or polydrug. Users who want to get clean and rid themselves of methamphetamine, cocaine, and/or fentanyl often find it difficult, essentially “chaining” themselves into a cycle of use that’s mostly impossible to break.
First responders and emergency department physicians lack sufficient tools to treat overdose. But what if there was a treatment that could eliminate toxins and restore normal bodily function within minutes? That’s the aim of Clear Scientific, a small biotech in Cambridge, MA that’s currently testing a treatment (CS-1103) using small molecules to “eat” toxins and deactivate their harmful effects almost instantly. With Phase I of a first-in-human (FIH) clinical trial ongoing, this revolutionary therapeutic is offering hope to those suffering from drug misuse and addiction a “chance to get better.”
Join us as Mitch Zakin, Co-founder and Executive Vice President of Innovation, and Winston Henderson, Co-founder and General Counsel, discuss their therapeutic approach, offer an update on their progress with CS-1103, how collaboration has enhanced their development, and how they hope it will eventually impact this epidemic.
Show Notes
Clear Scientific (https://www.clearsci.com/)
World Congress: Drug Modality Game Changers (https://www.criver.com/world-congress-drug-modality-game-changers)
Clear Scientific to Start Phase 1 Trial for Stimulant Antidote (https://www.clearsci.com/post/clear-scientific-to-start-phase-1-trial-for-stimulant-antidote)
Charles River | IND-Enabling Studies (https://www.criver.com/products-services/safety-assessment/ind-enabling-studies?region=3601)
Charles River | Small Molecule (https://www.criver.com/molecule-type/small-molecule)
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
4.8 / 5
22 ratings
Spotify
4.0 / 5
1 ratings
Contact Vital Science
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of Vital Science?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
